Evidence map›Paper›PMID 35301088›Full record

ArticleBiochimica et biophysica acta. Molecular basis of disease2022

Sphingolipid depletion suppresses UPR activation and promotes galactose hypersensitivity in yeast models of classic galactosemia.

Felipe S A Pimentel, Caio M Machado, Evandro A De-Souza, Caroline Mota Fernandes, Ana Luiza F V De-Queiroz, Guilherme F S Silva, Maurizio Del Poeta, Monica Montero-Lomeli, Claudio A Masuda

Open access · greenAbstract read
In one paragraph

Article in Biochimica et biophysica acta. Molecular basis of disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Felipe S A PimentelInstituto de Bioquímica Médica Leopoldo de Meis, Programa de Biologia Molecular e Biotecnologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Caio M MachadoInstituto de Bioquímica Médica Leopoldo de Meis, Programa de Biologia Molecular e Biotecnologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Evandro A De-SouzaInstituto de Bioquímica Médica Leopoldo de Meis, Programa de Biologia Molecular e Biotecnologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Caroline Mota FernandesDepartment of Microbiology and Immunology, Stony Brook University, Stony Brook, NY, USA.
Ana Luiza F V De-QueirozInstituto de Bioquímica Médica Leopoldo de Meis, Programa de Biologia Molecular e Biotecnologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Guilherme F S SilvaInstituto de Bioquímica Médica Leopoldo de Meis, Programa de Biologia Molecular e Biotecnologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Maurizio Del PoetaDepartment of Microbiology and Immunology, Stony Brook University, Stony Brook, NY, USA; Division of Infectious Diseases, Stony Brook, NY, USA; Veteran Administration Medical Center, Northport, New York, USA.
Monica Montero-LomeliInstituto de Bioquímica Médica Leopoldo de Meis, Programa de Biologia Molecular e Biotecnologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Claudio A MasudaInstituto de Bioquímica Médica Leopoldo de Meis, Programa de Biologia Molecular e Biotecnologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. Electronic address: cmasuda@bioqmed.ufrj.br.
Universidade Federal do Rio de Janeiro · BRStony Brook Medicine · USStony Brook University · US

Funding

New antifungals targeting the synthesis of fungal sphingolipidsR01AI116420 · NIAID · STATE UNIVERSITY NEW YORK STONY BROOK · PI Maurizio Del Poeta · 2016 to 2026
$7.6M
Lipid-mediated fungal pathogenesisR01AI125770 · NIAID · STATE UNIVERSITY NEW YORK STONY BROOK · PI DEL POETA, MAURIZIO · 2016 to 2025
$6.2M
Sphingosine-1-phosphate and cryptococcosisR01AI136934 · NIAID · STATE UNIVERSITY NEW YORK STONY BROOK · PI DEL POETA, MAURIZIO · 2018 to 2022
$2.5M
Role of host spingolipids against fungal infectionsI01BX002624 · VA · NORTHPORT VA MEDICAL CENTER · PI Maurizio Del Poeta · 2016 to 2026
–
BLRD Research Career Scientist Award ApplicationIK6BX005386 · VA · NORTHPORT VA MEDICAL CENTER · PI DEL POETA, MAURIZIO · 2021 to 2025
–
BLRD VA I01 BX002624BLRD VA IK6 BX005386NIAID NIH HHS R01 AI116420NIAID NIH HHS R01 AI125770NIAID NIH HHS R01 AI136934
6 · The paper itself

Abstract

Classic galactosemia is an inborn error of metabolism caused by deleterious mutations on the GALT gene, which encodes the Leloir pathway enzyme galactose-1-phosphate uridyltransferase. Previous studies have shown that the endoplasmic reticulum unfolded protein response (UPR) is relevant to galactosemia, but the molecular mechanism behind the endoplasmic reticulum stress that triggers this response remains elusive. In the present work, we show that the activation of the UPR in yeast models of galactosemia does not depend on the binding of unfolded proteins to the ER stress sensor protein Ire1p since the protein domain responsible for unfolded protein binding to Ire1p is not necessary for UPR activation. Interestingly, myriocin - an inhibitor of the de novo sphingolipid synthesis pathway - inhibits UPR activation and causes galactose hypersensitivity in these models, indicating that myriocin-mediated sphingolipid depletion impairs yeast adaptation to galactose toxicity. Supporting the interpretation that the effects observed after myriocin treatment were due to a reduction in sphingolipid levels, the addition of phytosphingosine to the culture medium reverses all myriocin effects tested. Surprisingly, constitutively active UPR signaling did not prevent myriocin-induced galactose hypersensitivity suggesting multiple roles for sphingolipids in the adaptation of yeast cells to galactose toxicity. Therefore, we conclude that sphingolipid homeostasis has an important role in UPR activation and cellular adaptation in yeast models of galactosemia, highlighting the possible role of lipid metabolism in the pathophysiology of this disease.

Indexed as

GalactosemiasGalactoseHumansSaccharomyces cerevisiaeSphingolipidsUTP-Hexose-1-Phosphate UridylyltransferaseGalactoseSphingolipidsUTP-Hexose-1-Phosphate UridylyltransferaseGalactosemiaInositolS. cerevisiaeSphingolipidsUnfolded protein response

Identifiers

PMID35301088
PMCPMC9326788
OpenAlexW4221018369

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.